Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Controlling Calcium Homeostasis Could Stabilize Alzheimer¡¯s Disease

By HospiMedica staff writers
Posted on 28 Jul 2008
Two new studies have found that controlling intracellular calcium homeostasis appears to play an important role in controlling levels of amyloid ¥â (A©¬) protein, a major component of the senile plaques that characterize Alzheimer¡¯s disease (AD).

Researchers at the department of neurobiology and behavior at the University of California Irvine (USA), reported that the sarco ER Ca2+-ATPase (SERCA) system, which pumps excess Ca2+ into the endoplasmic reticulum (ER) or its muscle equivalent, the sarcoplasmic reticulum (SR), has diminished activity in cells lacking presenilin-1 and presenilin-2 (PS1, PS2). More...
The deficiencies are associated at the cellular level with increased production of the proteotoxic peptide A©¬1-42, and at the organismal level with increased risk of early-onset AD. Modulation of SERCA activity on its own can affect the rate of A©¬ synthesis. Taken together, the data argue that PS1 and PS2 regulate intracellular Ca2+, and that calcium in turn influences production of A©¬ (and thereby the risk and progression of AD).

Another study, by researchers at the Feinstein Institute for Medical Research (Manhasset, NY, USA) identified CALHM1, a calcium pump on the plasma membrane (as opposed to the ER/SR membrane) that is also involved in A©¬ production. A naturally occurring polymorphism in the CALHM1 gene is strongly associated with AD; the authors propose that the mutation interferes with Ca2+ permeability and that this alters A©¬ expression via an as-yet-undetermined mechanism.

When combining the two studies, calcium is seen to be moving in opposite directions; SERCA pumps Ca2+ out of the cytosol into the ER/SR, so a deficiency in SERCA would increase cytosolic Ca2+. In contrast, CALHM1 pumps Ca2+ into the cytosol, so that a deficiency in that protein would decrease cytosolic Ca2+. However, deficiencies in either gene promote AD. The studies suggest that the similar effects on A©¬ levels are mediated by two very different mechanisms.

Amyloid ¥â is a peptide that is the main constituent of amyloid plaques in the brains of Alzheimer's disease patients. Amyloid ¥â also forms aggregates coating cerebral blood vessels in cerebral amyloid angiopathy. These plaques are composed of a tangle of regularly ordered fibrillar aggregates called amyloid fibers, a protein fold shared by other peptides such as prions associated with protein misfolding diseases. Research on laboratory rats suggests that the two-molecule, soluble form of the peptide is a causative agent in the development of AD.


Related Links:
Feinstein Institute for Medical Research
University of California Irvine

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.